Brentuximab Vedotin
| Evidence Level: L3 | Predicted Indications: 10 |
Table of Contents
- Brentuximab Vedotin
- Brentuximab Vedotin: From Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma to Follicular Lymphoma
Brentuximab Vedotin: From Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma to Follicular Lymphoma
One-Sentence Summary
Brentuximab vedotin (ADCETRIS) is an anti-CD30 antibody-drug conjugate. Published literature describes it as approved for CD30-positive lymphomas, chiefly Hodgkin lymphoma and systemic anaplastic large cell lymphoma. The TxGNN model predicts it may be effective for follicular lymphoma, but only 6 clinical trials (3 withdrawn, 1 recruiting single-arm) and 20 publications were retrieved, and none shows follicular-lymphoma-specific efficacy.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hodgkin lymphoma and systemic anaplastic large cell lymphoma (per published literature; the label indication text was not in the supplied data) |
| Predicted New Indication | Follicular lymphoma |
| TxGNN Prediction Score | 99.89% |
| Evidence Level | L3 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 1 (listed as BLA125388) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Brentuximab vedotin (BV) is an anti-CD30 antibody-drug conjugate. It delivers MMAE, a microtubule-disrupting agent, to CD30-positive cells. A structured mechanism-of-action entry was not available for this drug, so the description above comes from the mechanistic notes in the evidence pack.
Follicular lymphoma is a B-cell lymphoma, and BV is already used in other CD30-expressing lymphomas. However, CD30 is not a defining marker of follicular lymphoma. The link therefore depends on CD30-positive subsets or on transformed disease. The literature includes a case of grade I follicular lymphoma transformed to CD30+ anaplastic large cell lymphoma that responded completely to BV plus high-dose methotrexate. This is a single case and does not show activity in typical follicular lymphoma.
The very high TxGNN score is a model prediction, not clinical evidence. Most of the supplied literature concerns peripheral T-cell lymphoma rather than follicular lymphoma.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT04587687 | Phase 2 | Recruiting | 23 | BV + bendamustine in relapsed/refractory follicular lymphoma. Directly on-indication but single-arm, with no results yet. |
| NCT02594163 | Phase 2 | Terminated | 25 | Randomized rituximab + bendamustine ± BV in CD30+ relapsed/refractory DLBCL. Stopped early, so underpowered, and no efficacy results were supplied. |
| NCT01805037 | Phase 1/2 | Terminated | 20 | BV + rituximab as frontline therapy in CD30+ and/or EBV+ lymphomas. Mixed population, so a follicular-lymphoma-specific signal is unlikely. |
| NCT04138875 | Phase 2 | Withdrawn | 0 | Rituximab + BV ± bendamustine in newly diagnosed post-transplant lymphoproliferative disorders. No data. |
| NCT02623920 | Phase 2 | Withdrawn | 0 | BV + bendamustine + rituximab in CD30+ relapsed/refractory B-cell NHL. No data. |
| NCT04795869 | Phase 2 | Withdrawn | 0 | BV + pembrolizumab in recurrent peripheral T-cell lymphoma. No data. |
Literature Evidence
No randomized trials were retrieved. The list below is ordered as clinical studies, then reviews and case reports. None reports BV efficacy in typical follicular lymphoma.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 33320379 | 2021 | Clinical study | Eur J Haematol | BV added to ICE in relapsed/refractory peripheral T-cell lymphoma; not follicular-lymphoma-specific. |
| 40758949 | 2025 | Phase 2 study | Blood Adv | BV + gemcitabine followed by BV maintenance in relapsed/refractory CD30+ peripheral T-cell lymphoma (LYSA); not follicular-lymphoma-specific. |
| 34797505 | 2022 | Retrospective clinical study | Adv Ther | Real-world BV + cyclophosphamide, epirubicin and prednisone in untreated peripheral T-cell lymphoma; not follicular-lymphoma-specific. |
| 32476657 | 2020 | Case report | Gulf J Oncol | Grade I follicular lymphoma transformed to CD30+ ALK-negative anaplastic large cell lymphoma, with complete response to BV and high-dose methotrexate. |
| 38028985 | 2023 | Case report | Case Rep Hematol | Follicular lymphoma transformed to EBV+ DLBCL and EBV+ classic Hodgkin lymphoma; describes transformation, not BV treatment. |
| 35663281 | 2022 | Review | Leuk Res Rep | Immunotherapy in indolent non-Hodgkin lymphoma, including follicular lymphoma. |
| 38306597 | 2024 | Review | Blood | Treatment of common nodal peripheral T-cell lymphoma subtypes, including BV plus chemotherapy for CD30+ disease. |
| 39644004 | 2024 | Review | Hematology ASH Educ Program | Incorporating BV and other novel agents into peripheral T-cell lymphoma management. |
| 40517441 | 2025 | Review | Hematol Oncol | Peripheral T-cell lymphoma subtypes and emerging therapies. |
| 28967896 | 2018 | Review | Bone Marrow Transplant | Post-autologous-transplant maintenance in lymphoma, including rituximab maintenance in follicular lymphoma. |
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| BLA125388 | ADCETRIS (Seagen Inc.) | Injection, powder, lyophilized, for solution | Not provided in the supplied data |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy: an anti-CD30 antibody-drug conjugate with a cytotoxic MMAE payload (microtubule disruptor) |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Neuropathy and infection risk (suggested as guardrails in the evidence pack). For haematological and organ-function monitoring, refer to the package insert. |
| Handling Protection | Handle as a cytotoxic-payload product per institutional cytotoxic drug handling regulations |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: Follicular lymphoma is not a CD30-defined disease. The only on-indication trial is a small single-arm study with no results, and three of the six listed trials were withdrawn. The one randomized trial was terminated early. The supporting literature is mostly about peripheral T-cell lymphoma, and the very high TxGNN score is not clinical evidence.
To proceed, the following is needed:
- Results from NCT04587687 (BV + bendamustine in relapsed/refractory follicular lymphoma) and any data from the terminated NCT02594163
- CD30 expression prevalence data in follicular lymphoma, including transformed disease, to define a target subgroup
- The current US package insert (indications, warnings, contraindications) and the drug’s original indication list
- Structured mechanism-of-action data and a safety monitoring plan, with attention to neuropathy and infection risk
Related finding: the rank 4 prediction, B-cell neoplasm, has stronger support (L2, “Proceed with Guardrails”). It rests on multiple completed Phase 2 trials in CD30+ Hodgkin lymphoma, DLBCL and primary mediastinal B-cell lymphoma. That candidate should be verified against current labeling first, since it may be on-label.
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any clinical use.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.